Carotid Artery DiseaseARMOURNCT00744523
Proximal Protection With The Mo.Ma Device During Carotid Stenting
A study testing Mo.Ma cerebral protection device in people with Carotid Artery Disease, run by Medtronic Endovascular at 2 sites in United States.
Trial summary
The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery stenting Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carotid Artery Disease
- What is being tested?
- Mo.Ma cerebral protection device
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 262 participants
- Where
- 2 sitesUnited States
- Study dates
- Sep 2007to Mar 2009
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
General inclusion criteria Subject meets one or more of the high surgical risk criteria.
- Subject is ≥ 18 years old.
- Subject is a candidate for single lesion carotid artery stenting using a femoral arterial approach.
- Subject is willing and able to comply with follow-up evaluations at the specified times.
- Subject (or legal representative) understands the nature of the procedure and provides informed consent, prior to enrollment in the study.
- If female subject, is not currently pregnant and has stated that she has no intention of becoming pregnant during the study.
Angiographic inclusion criteria (as determined ≤ 30 days prior to procedure):
- Target lesion stenosis (% stenosis = (1-N/D) X 100)1, documented by selective angiography pre-intervention, is
- ≥ 80% stenosis for asymptomatic subjects or
- ≥ 50% stenosis for symptomatic subjects. Symptomatic is defined as carotid stenosis associated with ipsilateral transient or visual TIA evidenced byamaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral ischemic stroke within 6 months prior to enrollment.
- Target lesion is within the internal carotid artery and/or involves the bifurcation of the CCA.
- External carotid artery diameter where the Mo.Ma device will be positioned is 3-6 mm.
- Common carotid artery diameter where the Mo.Ma device will be positioned is 5-13 mm.
General exclusion criteria
- Subject has participated in, is participating in, or plans to participate in another clinical study that may affect either the pre-procedure or follow-up results.
- Subject has chronic or paroxysmal atrial fibrillation that is not treated by Coumadin.
- Subject has undergone prior stenting of the ipsilateral carotid artery.
- Subject's life expectancy is less than twelve months.
- Subject is unable to respond to external questions and stimuli and to exert a pressure with the contralateral hand.
- Subject is suffering from dementia.
- Subject has documented intolerance to BOTH heparin and Angiomax.
- Subject has an allergy or contraindication to acetylsalicylic acid (ASA).
- Subject has a documented allergy to the device materials.
- Subject has a documented allergy to radiographic contrast that cannot be pre-treated.
- Subject has a documented allergy or contraindication to BOTH clopidogrel and ticlopidine.
- Subject has had active bleeding diathesis requiring blood transfusion within one (1) month prior to index procedure.
- Subject has had an MI within 72 hours prior to carotid stenting.
- Subject has had coronary artery bypass graft (CABG) or vascular surgery within 30 days PRIOR TO index procedure (percutaneous coronary intervention is permissible provided cardiac enzymes are normal within 24 hours of index procedure), OR has planned CABG, vascular surgery, percutaneous coronary intervention (PCI), or has other invasive medical procedures planned within 30 days AFTER index procedure.(Unplanned urgent or emergent procedures may be performed at anytime as clinically indicated).
- Subject has a major residual neurological deficit (stroke scales: Barthel ≤ 60, NIH ≥ 15 or Rankin > 3) at pre-procedure neurological exam.
- Subject has had a transient ischemic attack (TIA) or amaurosis fugax within 48 hours prior to index procedure.
- Subject has had a stroke or retinal artery occlusion within one (1) month prior to index procedure.
- Subject had abnormal pre-intervention blood counts with platelets < 50,000/cubic mm or > 700,000/cubic mm or white blood cell count < 3,000/cubic mm.
- Subject has severe chronic renal failure (creatinine > 2.5 mg/dl).
- Subject is currently being treated for cerebral carcinoma or sarcoma.
- Subject has peripheral vascular disease, which precludes safe femoral artery sheath insertion.
- Subject is unable or unwilling to undergo insertion of a temporary pacemaker.
Angiographic exclusion criteria (as determined ≤ 30 days prior to procedure):
- The target carotid artery is completely occluded.
- The common carotid artery ostium has stenosis that requires treatment.
- Multiple carotid stenoses exist in the internal carotid artery (ICA) that cannot be covered by one stent.
- The presence of ipsilateral intracranial stenosis that requires treatment.
- The presence of any intracranial tumor(s), arteriovenous malformation(s) (AVMs), or aneurysm(s) requiring treatment.
- The inability to position a stiff .035" guidewire in the external carotid artery (ECA).
- Contralateral occlusion of internal carotid artery and vertebral arteries.
- Aortic arch anatomical anomalies that preclude the safe placement of the device.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
University at Buffalo Neurosurgery
Buffalo, New York, 14209
MidWest Cardiology Research Foundation
Columbus, Ohio, 43214
About this study
Official title: ARMOUR: Proximal Protection With The Mo.Ma Device During Carotid Stenting
The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery stenting
Read the detailed description
Test Device:
Mo.Ma™ Proximal Flow Blockage Cerebral Protection Device. Single size catheter device with a 9 French introducer sheath compatible shaft (outer diameter) and a 6 French compatible working channel (inner diameter), integrating two compliant balloons intended to achieve endovascular clamping of external carotid arteries (ECA) 3-6 mm in diameter and common carotid arteries (CCA) 5-13 mm in diameter.
Primary Objective:
Evaluate the safety and effectiveness of the Mo.Ma device for cerebral protection in the treatment of internal carotid artery (ICA) stenoses, which may or may not involve the bifurcation of the CCA, in subjects considered to be at high surgical risk for complications during carotid endarterectomy (CEA).
Primary Endpoint:
Major adverse cardiac and cerebrovascular events (MACCE) within 30 days of implantation. MACCE are defined as: any myocardial infarction (MI), stroke, or death through day 30 post-procedure.
- Conditions
- Carotid Artery Disease
- Being tested
- Mo.Ma cerebral protection device
- Keywords
- carotid artery stenting, stroke, cerebral protection, high surgical risk
- Medical subject headings
- Carotid Artery Diseases, Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mo.Ma cerebral protection deviceDevice
Also called Mo.Ma
Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
| Study group | Role | What they receive |
|---|---|---|
| Mo.ma cerebral protection device | Experimental | Mo.Ma cerebral protection device Receives: Device: Mo.Ma cerebral protection device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major Adverse Cardiac and Cerebrovascular Events (MACCE) Within 30 Days of the Procedure.
Number of subjects with one or more Major Adverse Cardiac and Cerebrovascular Events through 30 days after the procedure. MACCE are defined as: any myocardial infarction (MI), stroke, or death through day 30 post-procedure.
Measured: Up to 30 days after the procedure was performed
Secondary outcomes (6)
Device Success
Number of subjects in which the MO.MA was able to be positioned, deployed, and retrieved intact during the index procedure.
Measured: The entire duration of the index procedure
Technical Success
Number of subjects with device success and the ability to successfully implant a carotid stent and obtain a residual stenosis < 30% during the index procedure(as evaluated by the angiographic core laboratory).
Note: Three subjects were missing final angiographic results and therefore Technical and Procedural success could not be defined for these three subjects, thereby, decreasing the number of participants analyzed from 225 to 222.
Measured: The entire duration of the index procedure
Procedural Success
Number of subjects with technical success without the occurrence of any MACCE or unresolved antegrade flow blockage intolerance during the index hospitalization.
Note: Three subjects were missing final angiographic results and therefore Technical and Procedural success could not be defined for these three subjects, thereby, decreasing the number of participants analyzed from 225 to 222.
Measured: The entire duration of the index procedure through hospital discharge
Restenosis at 30 Days
Number of subjects with re-narrowing of the lesion at 30 days as defined as a >= 50% stenosis measured by duplex ultrasound scan.
Measured: Up to 30 days after the procedure was performed
Target Lesion Revascularization at 30 Days
Number of subjects with any repeat invasive procedure, including angioplasty, stenting, endarterectomy, or thrombolysis, performed to open or increase lumen diameter inside or within 10 mm of the previously treated lesion.
Measured: Up to 30 days after the procedure was performed
Access Site Adverse Events
Number of subjects with adverse events at the percutaneous access site as a result of the index procedure, including bruising, hematoma and bleeding requiring treatment by transfusion of blood products, surgical repair, ultrasound compression or thrombin injection.
Measured: Index Procedure through Hospital Discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2008 (estimated)
- Study startSep 2007
- Primary completionMar 2009
- Study completionMar 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Carotid Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 262 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medtronic Endovascular
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Gary Ansel, MD, Principal investigator, Midwest Cardiology Research FoundationL. Nelson Hopkins, MD, Principal investigator, University at Buffalo Neurosurgery
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00744523
- Sponsor's protocol ID
- P-2850
- Acronym
- ARMOUR
- Status last verified
- Jan 2016
- First submitted
- 29 Aug 2008
- Last updated
- 26 Feb 2016
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 26 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ARMOUR: Proximal Protection With The Mo.Ma Device During Carotid Stenting
- ClinicalTrials.gov ID
- NCT00744523
- Acronym / sponsor ID
- ARMOUR / P-2850
- Conditions
- Carotid Artery Disease
- Keywords
- carotid artery stenting, stroke, cerebral protection, high surgical risk
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 262 participants (actual)
- Lead sponsor
- Medtronic EndovascularIndustry (pharma, biotech, devices)
- Study start
- Sep 2007
- Primary completion
- Mar 2009 (actual)
- Study completion
- Mar 2009 (actual)
- First posted
- 1 Sep 2008 (estimated)
- Results
- Posted 5 May 2010
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery stenting
Detailed description
Test Device:
Mo.Ma™ Proximal Flow Blockage Cerebral Protection Device. Single size catheter device with a 9 French introducer sheath compatible shaft (outer diameter) and a 6 French compatible working channel (inner diameter), integrating two compliant balloons intended to achieve endovascular clamping of external carotid arteries (ECA) 3-6 mm in diameter and common carotid arteries (CCA) 5-13 mm in diameter.
Primary Objective:
Evaluate the safety and effectiveness of the Mo.Ma device for cerebral protection in the treatment of internal carotid artery (ICA) stenoses, which may or may not involve the bifurcation of the CCA, in subjects considered to be at high surgical risk for complications during carotid endarterectomy (CEA).
Primary Endpoint:
Major adverse cardiac and cerebrovascular events (MACCE) within 30 days of implantation. MACCE are defined as: any myocardial infarction (MI), stroke, or death through day 30 post-procedure.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Mo.ma cerebral protection device | Experimental | Device: Mo.Ma cerebral protection deviceMo.Ma cerebral protection device |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mo.Ma cerebral protection deviceAlso: Mo.MaProximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel. | Device | Mo.ma cerebral protection device |
Primary outcome
Major Adverse Cardiac and Cerebrovascular Events (MACCE) Within 30 Days of the Procedure.
Time frame: Up to 30 days after the procedure was performed
Number of subjects with one or more Major Adverse Cardiac and Cerebrovascular Events through 30 days after the procedure. MACCE are defined as: any myocardial infarction (MI), stroke, or death through day 30 post-procedure.
6 secondary outcomes
Device Success
Time frame: The entire duration of the index procedure
Technical Success
Time frame: The entire duration of the index procedure
Procedural Success
Time frame: The entire duration of the index procedure through hospital discharge
Restenosis at 30 Days
Time frame: Up to 30 days after the procedure was performed
Target Lesion Revascularization at 30 Days
Time frame: Up to 30 days after the procedure was performed
Access Site Adverse Events
Time frame: Index Procedure through Hospital Discharge
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Feb 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Carotid Artery Disease
Active, not recruitingObservational study
Symptomatic Carotid Outcomes Registry
Carotid Stenosis, Ischemic Stroke
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Not yet recruitingObservational study
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)
Carotid Atherosclerosis, Carotid Artery Stenosis Asymptomatic
Not yet recruiting
UltraTrac for Cardiac Output Monitoring in Congenital Heart Disease
Congenital Heart Disease, Cardiac Output
Not yet recruitingObservational study
Common Carotid Artery-Renal Artery-Femoral Artery Survey for Hypertension
Hypertension, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gary Ansel, MD principal investigator
Midwest Cardiology Research Foundation
L. Nelson Hopkins, MD principal investigator
University at Buffalo Neurosurgery
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mo.Ma cerebral protection device in people with Carotid Artery Disease, run by Medtronic Endovascular at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 May 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major Adverse Cardiac and Cerebrovascular Events (MACCE) Within 30 Days of the Procedure. (time frame: Up to 30 days after the procedure was performed). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2016.